SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Accretive Health, Inc. (OTCMKTS:ACHI), a leading company in healthcare sector has introduced some changes in the senior management. As per the reports, these changes have been made in the board of director after a few board members decided to move on.

Michael Cline, Board Member, Accretive Health notified the company about his resignation on May 14, while Mary A. Tolan and Arthur H. Spiegel, III notified on the next day i.e. May 15 about their resignation. Apart from them, other members like Stanley N. Logan, Steven N. Kaplan and Mark A. Wolfson requested the Board of Directors to not considering their names for re-elections. Stephen F. Schuckenbrock was among others who decided to end his journey with Accretive Health Board in May after the execution of Omnibus Amendment.

Changes in Board of Directors:

So many resignations and discontinuation of Association forced the company to take quick decision, as a result of which board came up with an alternative plan on May 19, 2015. As per the reports, the board of directors of the company decided to enhance the number of directors to 14, so that it could fall into a stable condition.

Michael B. Hammond was elected as a Class I director of Accretive Health, Inc. (OTCMKTS:ACHI) among others. Amir Dan Rubin and Dr. Arthur Klein were selected as Class II directors, while Lawrence B. Leisure and Charles J. Ditkoff were chosen as Class III directors of the company. All the elected directors will serve in their positions until the 2015 AGM takes place and the new directors are named.

Reports claim that Rubin, Hammond, Ditkoff, Dr. Klein and Leisure were elected to their positions after the Nominating and Corporate Governance Committee of the Board nominated their names. All the newly elected directors come with a huge experience and expertise and suppose to take Accretive to newer heights in the coming days.